Alzheimer's Disease Market Analysis 2034: EMA, PDMA, FDA Approvals, Pipeline, Clinical Trials, Symptoms, Revenue, Statistics, NICE Approvals and Companies by DelveInsight

(Albany, USA) DelveInsight's "Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Alzheimer's Disease, historical and forecasted epidemiology as well as the Alzheimer's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Alzheimer's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Alzheimer's Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Alzheimer's Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Alzheimer's Disease market.

Request for a Free Sample Report @ Alzheimer's Disease Market Forecast - https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Alzheimer's Disease Market Report are:
• According to DelveInsight, Alzheimer's Disease market size is expected to grow at a decent CAGR by 2034.
• Leading Alzheimer's Disease companies working in the market are Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., Stemedica Cell Technologies, Inc. and many others.
• The Alzheimer's Disease market size was valued ~USD 3,610 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, Annovis Bio Inc. announced clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen.
• In May 2025, Hoffmann-La Roche announced clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain.
• In February 2025, Annovis Bio's phase 3 Alzheimer's trial protocol was accepted, aiming to accelerate development and support a New Drug Application for buntanetap.
• In February 2025, Johnson & Johnson's posdinemab, an anti-tau therapy for Alzheimer's, was granted fast track designation, addressing tau pathology to slow cognitive decline.
• In January 2025, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in the U.S. After 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.
• In October 2024, Annovis Bio Inc. announced that it successfully completed an End-of-Phase 2 meeting with the FDA for its Alzheimer's drug, buntanetap. The FDA has approved the progression to Phase 3 pivotal trials, following data demonstrating symptomatic improvement in patients with early Alzheimer's. Annovis is now poised to file New Drug Applications (NDAs) for both short-term and long-term efficacy in treating early Alzheimer's disease.
• In September 2024, Eli Lilly's Alzheimer's treatment, Kisunla (donanemab), has been approved in Japan, following its U.S. approval in July. Kisunla becomes the second amyloid-targeting therapy approved in Japan, after Eisai and Biogen's Leqembi (lecanemab). It is indicated for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment and mild dementia, who have confirmed amyloid pathology.
• In 2023, the United States represented the largest market for Alzheimer's disease, accounting for approximately 54% of the total market size across the 7MM, compared to other major markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany had the largest market size for Alzheimer's disease among the EU countries, with USD 267 million, while the UK had the smallest market size, approximately USD 104 million.
• In 2023, the market size for Alzheimer's disease in Japan was estimated to be approximately USD 845 million.
• According to DelveInsight's assessment, the total diagnosed prevalent cases of Alzheimer's disease in Japan were estimated to be approximately 3.92 million in 2023.
• In 2023, the United States accounted for about 44% of the diagnosed Alzheimer's disease cases across the 7MM, with approximately 6.98 million cases. This number is expected to grow by 2034, according to DelveInsight's estimates.
• In Japan, there were approximately 1.39 million diagnosed male cases and 2.53 million diagnosed female cases of Alzheimer's disease in 2023, reflecting the gender distribution within the population.
• In the US, age-specific cases of Alzheimer's disease are divided into four groups: under 65, 65-74, 75-84, and 85+ years. In 2023, the 75-84 age group had the highest prevalence, with approximately 2.79 million cases, while the under-65 group had the lowest, with around 175 thousand cases.
• Key Alzheimer's Disease Therapies: BAN2401, Gantenerumab, ALZT-OP1, Bryostatin-1, ALZT-OP1, Tricaprilin
• The Alzheimer's Disease epidemiology based on gender analyzed that more women than men have Alzheimer's or other dementias

Alzheimer's disease Overview
Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia, affecting millions globally. It primarily impacts memory, thinking, and behavior, leading to significant impairments in daily functioning. Alzheimer's is characterized by the accumulation of amyloid plaques and tau tangles in the brain, which disrupt neuron communication and lead to cell death.
The disease typically manifests in individuals over the age of 65, with early symptoms including memory loss, confusion, and difficulty with language. As it advances, symptoms exacerbate to severe cognitive decline, loss of independence, and inability to perform basic tasks.
While the exact cause of Alzheimer's remains unknown, risk factors include age, genetics, family history, and lifestyle factors such as cardiovascular health. Diagnosis involves a combination of medical history, cognitive tests, and brain imaging.
Currently, there is no cure for Alzheimer's, but treatments are available to manage symptoms and improve quality of life. Medications like cholinesterase inhibitors and memantine can help, alongside lifestyle interventions and supportive care. Ongoing research aims to better understand the disease and develop effective treatments, with hopes of finding a cure in the future.

Learn more about Alzheimer's Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Alzheimer's Disease Treatment Market - https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Market
The Alzheimer's Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alzheimer's Disease market trends by analyzing the impact of current Alzheimer's Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Alzheimer's Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alzheimer's Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Alzheimer's Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

Alzheimer's Disease Epidemiology
The Alzheimer's Disease epidemiology section provides insights into the historical and current Alzheimer's Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alzheimer's Disease market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Alzheimer's Disease Epidemiology @ Alzheimer's Disease Prevalence - https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Drugs Uptake
This section focuses on the uptake rate of the potential Alzheimer's Disease drugs recently launched in the Alzheimer's Disease market or expected to be launched in 2020-2034. The analysis covers the Alzheimer's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Alzheimer's Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alzheimer's Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alzheimer's Disease Pipeline Development Activities
The Alzheimer's Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Alzheimer's Disease companies involved in developing targeted therapeutics.
• Lecanemab (BAN2401): Eisai/ BioArctic AB (Sweden)
• Tricaprilin: Cerecin
• Aducanumab (BIIB037): Biogen
• Gantenerumab (RG1450, RO4909832): Chugai Pharmaceuticals (Hoffmann-La Roche)
• Brexpiprazole (REXULTI / RXULTI): Otsuka Pharmaceutical
• AL002: Alector
• ALZT-OP1: AZ Therapies
• Brilaroxazine (RP5063): Reviva Pharmaceuticals
• BIIB076: Neurimmune

Request for a sample report to understand more about the Alzheimer's Disease pipeline development activities @ Alzheimer's Disease Drugs Market - https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Therapeutics Assessment
Major key companies are working proactively in the Alzheimer's Disease Therapeutics market to develop novel therapies which will drive the Alzheimer's Disease treatment markets in the upcoming years are Eisai/ BioArctic AB, Biogen, Otsuka Pharmaceutical, Hoffmann-La Roche/Chugai Pharmaceuticals, Alector, AbbVie, Reviva Pharmaceutical, AZ Therapies, Cerecin, Anavex Life Sciences Corp., Neurimmune, and others.

Learn more about the emerging Alzheimer's Disease therapies & key companies @ Alzheimer's Disease Clinical Trials and Advancements - https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Report Key Insights

1. Alzheimer's Disease Patient Population
2. Alzheimer's Disease Market Size and Trends
3. Key Cross Competition in the Alzheimer's Disease Market
4. Alzheimer's Disease Market Dynamics (Key Drivers and Barriers)
5. Alzheimer's Disease Market Opportunities
6. Alzheimer's Disease Therapeutic Approaches
7. Alzheimer's Disease Pipeline Analysis
8. Alzheimer's Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Alzheimer's Disease Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Alzheimer's Disease Competitive Intelligence Analysis
4. Alzheimer's Disease Market Overview at a Glance
5. Alzheimer's Disease Disease Background and Overview
6. Alzheimer's Disease Patient Journey
7. Alzheimer's Disease Epidemiology and Patient Population
8. Alzheimer's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Alzheimer's Disease Unmet Needs
10. Key Endpoints of Alzheimer's Disease Treatment
11. Alzheimer's Disease Marketed Products
12. Alzheimer's Disease Emerging Therapies
13. Alzheimer's Disease Seven Major Market Analysis
14. Attribute Analysis
15. Alzheimer's Disease Market Outlook (7 major markets)
16. Alzheimer's Disease Access and Reimbursement Overview
17. KOL Views on the Alzheimer's Disease Market
18. Alzheimer's Disease Market Drivers
19. Alzheimer's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Alzheimer's Disease Market report here @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Actinic Keratosis Market: https://www.delveinsight.com/infographics/actinic-keratosis-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Ashermans Syndrome Market: https://www.delveinsight.com/report-store/ashermans-syndrome-market
• Bacterial Skin Diseases Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Biliary Stents Market: https://www.delveinsight.com/report-store/biliary-stents-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Bone Densitometers Market: https://www.delveinsight.com/blog/bone-densitometers-market-analysis
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Diabetic Neuropathy Market: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Exocrine Pancreatic Insufficiency Market: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
• Head And Neck Squamous Cell Carcinoma Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/infographics/diabetic-foot-ulcers-dfus-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Pruritus Market: https://www.delveinsight.com/report-store/chronic-pruritus-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Wound Closure Devices Market: https://www.delveinsight.com/report-store/wound-closure-device-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-atrt-epidemiology-forecast
• Bladder Cancer Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-epidemiology-forecast
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Continuous Renal Replacement Therapy Machines Market: https://www.delveinsight.com/report-store/continuous-renal-replacement-therapy-machines-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market-forecast
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-pipeline-insight
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Astigmatism Market: https://www.delveinsight.com/report-store/astigmatism-market
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast
• Pneumoconiosis Market: https://www.delveinsight.com/report-store/pneumoconiosis-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Sts Devices Market: https://www.delveinsight.com/report-store/sts-devices-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.